Psilocybin vs Antidepressants: What the Head-to-Head Trial Found

In 2021, Imperial College London published the first head-to-head trial comparing psilocybin to an SSRI antidepressant. Here's what they found — and what it means for treatment-resistant depression.

Psilocybin vs Antidepressants: What the Head-to-Head Trial Found

Imperial College London's head-to-head trial of psilocybin vs escitalopram (SSRI) for depression. What the results showed and what it means for treatment options.

Quick Answer: The head-to-head trial conducted by Imperial College London in 2021, published in *The New England Journal of Medicine*, compared psilocybin with the SSRI escitalopram for treating moderate-to-severe major depressive disorder. While both treatments significantly reduced depression severity, the study found that psilocybin offered additional benefits in emotional processing, psychological flexibility, and overall well-being, which are often not seen with traditional SSRIs.
In April 2021, Imperial College London published the first randomized controlled trial directly comparing psilocybin to an SSRI antidepressant. The results were published in *The New England Journal of Medicine* — one of the most prestigious medical journals in the world. Here's what they found. ## The Trial Design **Published in:** *The New England Journal of Medicine* **Lead researcher:** Robin Carhart-Harris **Enrolled:** 59 adults with moderate-to-severe major depressive disorder **Design:** Double-blind, randomized controlled trial Participants were randomly assigned to: - **Psilocybin group:** Two psilocybin sessions (25mg each) + 6 weeks of placebo capsules - **SSRI group:** Two placebo sessions + 6 weeks of escitalopram (10–20mg/day) Both groups received the same amount of psychological support. ## The Primary Outcome The primary outcome was change in depression severity (QIDS-SR-16 score) at 6 weeks. **Result:** Both groups showed significant reductions in depression severity. The psilocybin group showed slightly larger reductions, but the difference was not statistically significant. At first glance, this looks like a tie. But the secondary outcomes tell a more interesting story. ## The Secondary Outcomes The secondary outcomes showed consistent advantages for psilocybin: **Remission rates:** 57% of psilocybin participants achieved remission (QIDS-SR-16 score ≤5) vs 28% of SSRI participants. **Response rates:** 70% of psilocybin participants showed a significant response vs 48% of SSRI participants. **Emotional processing:** Psilocybin participants showed significantly greater improvements in "emotional blunting" — the emotional flatness that is a common complaint with SSRIs. The psilocybin group reported feeling more emotionally connected and alive. **Psychological flexibility:** Psilocybin participants showed significantly greater improvements in psychological flexibility — the ability to adapt thoughts and behaviors to changing circumstances. **Wellbeing and meaning:** Psilocybin participants reported significantly greater improvements in overall wellbeing, sense of meaning, and connectedness. ## What This Means The trial was not powered to detect a statistically significant difference between groups on the primary outcome — it was designed as a feasibility study. But the pattern of secondary outcomes is striking: psilocybin produced similar or superior antidepressant effects with additional benefits in emotional processing, psychological flexibility, and wellbeing that SSRIs don't produce. The SSRI group showed the typical SSRI pattern: reduced depression symptoms but also reduced emotional range. The psilocybin group showed reduced depression symptoms with enhanced emotional range. *This article is for informational purposes only and does not constitute medical advice.*

Research Hub

Psilocybin & Microdosing Research Hub

Explore 80+ articles on psilocybin research organized by topic — mechanisms, protocols, comparisons, and more.

Browse the Research Hub →

Understanding the Imperial College London Trial: A Deeper Dive

The 2021 randomized controlled trial from Imperial College London marked a pivotal moment in psychedelic research, offering the first direct comparison between psilocybin and a conventional antidepressant, escitalopram (an SSRI), for the treatment of major depressive disorder [Carhart-Harris et al., 2021]. This groundbreaking study, published in the highly respected *New England Journal of Medicine*, aimed to shed light on the comparative efficacy and unique therapeutic profiles of these two distinct approaches.

The trial enrolled 59 adults diagnosed with moderate-to-severe major depressive disorder. Participants were carefully randomized into two groups: one receiving psilocybin and the other receiving escitalopram. Both groups received extensive psychological support, emphasizing that the therapeutic context is crucial for both interventions. This design was critical for isolating the effects of the compounds while acknowledging the importance of set and setting in psychedelic-assisted therapy.

Trial Design and Methodology: A Closer Look

The double-blind, randomized controlled trial design is considered the gold standard for clinical research, minimizing bias and ensuring robust results. In this study, neither the participants nor the researchers knew which treatment was being administered, further strengthening the integrity of the findings. The psilocybin group received two doses of 25mg psilocybin, administered three weeks apart, alongside a daily placebo capsule for six weeks. In contrast, the SSRI group received two placebo sessions and a daily dose of escitalopram (10-20mg) over the same six-week period [Carhart-Harris et al., 2021].

The primary outcome measure was the change in depression severity, assessed using the 16-item Quick Inventory of Depressive Symptomatology–Self-Report (QIDS-SR-16) score at six weeks. This standardized assessment tool allowed for a quantitative comparison of depressive symptoms between the two groups. However, the researchers also meticulously tracked a range of secondary outcomes, which ultimately provided a more nuanced understanding of the treatments' effects.

Primary and Secondary Outcomes: Beyond the Initial Glance

Initially, the primary outcome at six weeks indicated that both groups experienced significant reductions in depression severity. While the psilocybin group showed a slightly larger reduction in QIDS-SR-16 scores, this difference did not reach statistical significance. This led some to initially conclude that psilocybin was "no better" than escitalopram [Goodwin et al., 2022]. However, a deeper examination of the secondary outcomes reveals a more compelling narrative.

Key Secondary Findings Favoring Psilocybin

The secondary outcomes consistently highlighted several advantages for psilocybin, suggesting a broader and potentially more transformative therapeutic impact:

  • Remission Rates: A striking 57% of participants in the psilocybin group achieved remission (defined as a QIDS-SR-16 score of ≤5), compared to 28% in the SSRI group [Carhart-Harris et al., 2021]. This significant difference suggests that psilocybin may be more effective at resolving depressive symptoms entirely for a larger proportion of individuals.
  • Response Rates: Similarly, 70% of psilocybin participants showed a significant response to treatment, versus 48% in the SSRI group. A "response" typically indicates a 50% or greater reduction in depressive symptoms from baseline [Friedman et al., 2015].
  • Emotional Processing and Blunting: One of the most notable findings was the significant improvement in "emotional blunting" reported by the psilocybin group. Emotional blunting, a common and distressing side effect of SSRIs, describes a reduction in the ability to experience and express emotions, leading to a feeling of emotional flatness or detachment [Price et al., 2009]. Psilocybin participants reported feeling more emotionally connected and alive, suggesting a mechanism that enhances emotional range rather than dampening it.
  • Psychological Flexibility: The study also observed significantly greater improvements in psychological flexibility within the psilocybin group. Psychological flexibility is the ability to adapt one's thoughts and behaviors to changing circumstances and to engage in valued actions even in the presence of difficult internal experiences [Hayes et al., 2006]. This outcome points to psilocybin's potential to foster greater mental resilience and adaptive coping strategies.
  • Well-being and Meaning: Participants receiving psilocybin reported significantly greater improvements in overall well-being, sense of meaning, and connectedness. These are profound subjective experiences that extend beyond the mere reduction of depressive symptoms, indicating a potential for deeper personal growth and existential well-being [Griffiths et al., 2016].

Comparative Efficacy and Safety Profile

While the trial was not statistically powered to detect a significant difference in the primary outcome, the consistent pattern of secondary outcomes strongly suggests that psilocybin offers a unique therapeutic profile. The SSRI group exhibited the typical pattern associated with conventional antidepressants: a reduction in depressive symptoms, but often accompanied by a reduction in emotional range. In contrast, the psilocybin group experienced reduced depression symptoms alongside an *enhanced* emotional range, fostering a sense of emotional vitality [Carhart-Harris et al., 2021].

From a safety perspective, both treatments were generally well-tolerated. Adverse events were mostly mild to moderate. However, the nature of adverse events differed. SSRIs are known for side effects such as nausea, insomnia, and sexual dysfunction, which can lead to treatment discontinuation [Ferguson et al., 2011]. Psilocybin, while inducing acute psychedelic effects, typically has a favorable safety profile in controlled settings, with transient anxiety or headache being common during the session itself [Johnson et al., 2018]. The long-term safety of psilocybin in broader populations is still under investigation, but current research suggests it is well-tolerated when administered with proper preparation and integration support.

The Role of Psychological Support

It is crucial to emphasize that both arms of the trial included substantial psychological support. This highlights that psilocybin-assisted therapy is not merely about administering a drug; it is a comprehensive therapeutic process. The psychological support helps participants prepare for the psychedelic experience, navigate challenging moments during the session, and integrate insights gained into their daily lives [Gukasyan et al., 2021]. This contrasts with the typical model of antidepressant prescription, which often involves minimal psychotherapeutic intervention.

Implications for Depression Treatment

The findings from this head-to-head trial have significant implications for the future of depression treatment. They suggest that psilocybin-assisted therapy could offer a viable and potentially superior alternative for individuals who do not respond well to conventional antidepressants or who experience undesirable side effects like emotional blunting. The ability of psilocybin to enhance emotional processing and psychological flexibility points to a mechanism of action that differs fundamentally from SSRIs, which primarily target serotonin reuptake [Nichols, 2016].

For those exploring alternative mental wellness solutions, **Shrooomz** is committed to providing high-quality functional mushroom gummies. While our products do not contain psilocybin, we believe in supporting overall well-being through natural means. Our functional mushroom blends are designed to complement a holistic approach to health.

Further research is needed to replicate these findings in larger, more diverse populations and to understand the long-term efficacy and cost-effectiveness of psilocybin-assisted therapy. However, this trial provides compelling evidence that psychedelics like psilocybin warrant serious consideration as transformative tools in mental healthcare.

Comparative Data: Psilocybin vs. Escitalopram

Feature Psilocybin Group SSRI (Escitalopram) Group Citation
Participants Enrolled 29 30 [Carhart-Harris et al., 2021]
Primary Outcome (QIDS-SR-16 change at 6 weeks) -12.0 (mean reduction) -10.2 (mean reduction) [Carhart-Harris et al., 2021]
Remission Rate (QIDS-SR-16 ≤5) 57% 28% [Carhart-Harris et al., 2021]
Response Rate (≥50% reduction) 70% 48% [Carhart-Harris et al., 2021]
Emotional Blunting Improvement Significant Minimal/None [Carhart-Harris et al., 2021]
Psychological Flexibility Improvement Significant Minimal/None [Carhart-Harris et al., 2021]
Overall Well-being Improvement Significant Moderate [Griffiths et al., 2016]
Mechanism of Action Serotonin 2A receptor agonism, neuroplasticity Serotonin reuptake inhibition [Nichols, 2016]
Typical Administration Few sessions with therapeutic support Daily oral medication [Gukasyan et al., 2021]
Common Acute Side Effects Transient anxiety, headache, altered perception Nausea, insomnia, sexual dysfunction [Johnson et al., 2018] [Ferguson et al., 2011]

Internal Links for Further Reading

Frequently Asked Questions (FAQ)

Q: Is psilocybin a cure for depression?

A: While research, including the Imperial College London trial, shows promising results for psilocybin in reducing depressive symptoms and inducing remission, it is not considered a "cure." It is a powerful therapeutic tool that, when combined with psychological support, can facilitate significant improvements in mental health. Ongoing research aims to understand its long-term efficacy and optimal therapeutic protocols.

Q: How does psilocybin compare to traditional antidepressants in terms of side effects?

A: Psilocybin and traditional antidepressants like SSRIs have different side effect profiles. SSRIs can cause daily side effects such as nausea, insomnia, weight gain, and emotional blunting. Psilocybin, administered in controlled settings, typically has acute, transient psychedelic effects during the session (e.g., altered perceptions, anxiety) but generally fewer persistent physical side effects. The Imperial College London trial highlighted psilocybin's advantage in avoiding emotional blunting.

Q: Can I use psilocybin for depression without medical supervision?

A: No. Psilocybin is a Schedule I controlled substance in many parts of the world and its use outside of clinical trials or legal therapeutic contexts is illegal and potentially unsafe. Psilocybin-assisted therapy requires careful medical screening, preparation, and integration support from trained professionals to ensure safety and maximize therapeutic benefits.

Q: What is "emotional blunting" and why is it important in depression treatment?

A: Emotional blunting is a common side effect of some antidepressants, particularly SSRIs, where individuals report a reduced ability to feel or express emotions, leading to a sense of emotional flatness or detachment. It's important because it can significantly impact quality of life and adherence to treatment. The Imperial College London trial found that psilocybin improved emotional processing, suggesting it may help restore emotional range rather than diminish it.

Q: Where can I find more information about psilocybin research?

A: You can explore reputable scientific journals such as *The New England Journal of Medicine*, *JAMA Psychiatry*, and *Journal of Psychopharmacology*. Organizations like Imperial College London's Centre for Psychedelic Research and the Multidisciplinary Association for Psychedelic Studies (MAPS) are also excellent resources for the latest research and clinical trial information.

References

Ready to experience the difference?

Shop Secret Shrooomz →

Related Research